Abstract
Elacestrant, the leading oral drug candidate designed to degrade the estrogen receptor, continues to show prolonged antitumor activity, according to data presented at the ESMO Congress 2022. But not all oral selective estrogen receptor degraders have demonstrated impressive efficacy. In August, Sanofi announced that it was ending development of amcenestrant after an interim analysis of a pivotal phase III trial found that the study would likely end in failure.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
